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showing the cost increase for health services 
to manage HCV positive patients, leading to 
the conclusion that a lack of treatment of the 
pathology would lead to an increase of the 
disease burden due to HCV induced patholo-
gies and the related worsening of the health 
condition of HCV positive patients [6-9].
Among HCV genotypes, genotype 3 is asso-
ciated with higher HCC incidence and with 
accelerated fibrosis progression [10,11], and 
only two treatments are recommended by 
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Infections due to Hepatitis C Virus (HCV) 
represent a global health problem, affecting 
patients worldwide [1] with different pre-
valence and incidence among countries [2-
4]. They may progress to chronic cirrhosis, 
hepatocellular carcinoma (HCC), hepatic 
decompensation and may lead to liver tran-
splant [5].
The economic and social impact of the di-
sease was investigated in different contexts, 
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aBstract
BACKGROUND: Hepatitis C Virus (HCV) infection represents a global health problem, leading to chronic cirrhosis, 
hepatocellular carcinoma (HCC), hepatic decompensation and liver transplant. The aim of the study was the evaluation of 
the impact on the budget of the Italian National Health Service (INHS) of the use of Daclatasvir (DCV) for the treatment 
of HCV genotype 3 in patients with advanced fibrosis.
METHODS: An analytical decision model with a five year time horizon was implemented. Two scenarios were considered: 
a. 100% of market share for Interferon (INF-α)+Ribavirin (RBV)+Sofosbuvir (SOF) for 12 weeks; b. SOF+DCV+RBV for 
24 weeks with annual market shares of 50% in 2015 and 2016, 55% in 2017 and 2018, 60% in 2019, and INF-α+RBV+SOF 
for 12 weeks with the remaining market shares. Every annual cycle a percentage of patients equal to the effectiveness of 
the antiviral treatment reach a sustained virologic response and during the first year of treatment patients may experience 
treatment related adverse events. The costs considered (2015) are those of the antiviral therapy, and direct medical costs for 
health state and adverse events management. Univariate and multivariate sensitivity analyses were performed.
RESULTS: DCV would lead to an increase of the costs for the INHS (year 1 +21.31 millions, year 2 +21.35 millions, year 
3 + 23.37 millions, year 4 + 23.26 millions and year 5 +16.37 millions). The sensitivity analysis confirmed the robustness 
of the results.
CONCLUSIONS: The use of DCV is likely to have a short term impact on the INHS budget increasing resources use 
compared to the sole use of INF-α+RBV+SOF. However, a trend of reduction of the costs increase is observed due to the 
management of health states and adverse events which may lead to the possibility to reduce costs in the long term. 
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the Guidelines of the European Association 
for the Study of Liver for the treatment of 
HCV genotype 3 infected patients with com-
pensated cirrhosis [12]: sofosbuvir (SOF) + 
daclatasvir (DCV) + ribavirine (RBV) for 24 
weeks and peg interferon α (INF-α) + RBV + 
SOF for 12 weeks.
Due to the high cost of new HCV antiviral 
treatments and in absence of scientific evi-
dence about their economic impact on the 
Italian National Health Service (NHS), the 
study presented aimed at evaluating the im-
pact on the budget of the Italian NHS of the 
use of daclatasvir for the treatment of HCV 
genotype 3 infected patients compared with 
the sole use of INF-α + RBV + SOF.
Materials and Methods
An analytical decision model was implemen-
ted to forecast the impact on the budget of 
the Italian NHS of the use of DCV in a five 
year time horizon for the treatment of HCV 
positive patients [13].
The patients eligible to antiviral treatment 
were those with a fibrosis rate of 3 and 4 (F3 
and F4), as recommended by the Italian NHS. 
The number of eligible patients was estima-
ted using published prevalence and incidence 
data, as reported in Table I.
Two scenarios were structured based on the 
recommendations of the guidelines of the 
European Association for the Study of Li-
ver [12]. In details the only two treatments 
recommended for cirrhotic genotype 3 HCV 
infected patients were considered in two sce-
narios, one not considering the use of DCV, 
therefore having a 100% market share of 
INF-α + RBV + SOF for 12 weeks from 2015 
to 2019 (scenario 1); the second one introdu-
cing in the base case scenario SOF + DCV + 
RBV for 24 weeks with the following annual 
market shares: 50% in 2015 and 2016, 55% 
in 2017 and 2018, and 60% in 2019 (scenario 
2). The market shares were based on experts’ 
opinions.
Patients enter the model in one of the fol-
lowing health states [15]: F3 (60%), F4 
(16%), decompensated cirrhosis (3%), 
HCC (19%), liver transplant (2%). Each 
year patients may change their health sta-
tes with probabilities based on previously 
published works [18,19], as presented in 
Table II.
Every annual cycle a percentage of patients, 
equal to the effectiveness of the antiviral tre-
atment, reach a sustained virologic respon-
se (SVR). During the first year of treatment 
patients may experience treatment related 
adverse events (anemia and rash) with rates 
derived from literature. The effectiveness 
(SVR at 12 weeks after the end of the tre-
atment) and adverse events rates are reported 
in Table III. Due to lack of data concerning 
the effectiveness and the efficacy of the tre-
atments among patients affected with decom-
pensated cirrhosis, HCC and eligible for liver 
transplant, the same effectiveness observed 
in patients with fibrosis stages 3 and 4 was 
considered.
The costs considered within the model are 
those of the antiviral therapy, direct medical 
costs for the management of the health state 
Pts (n.) % of the previous category source
Italian population (1st January 2014) 60,782,668 [14]
HCV prevalence 2,725,359 4.5 [15]
HCV positive patients 300,000 11.0 [16]
HCV positive patients eligible to treatment (F3 – F4) 24,600 8.2 [16]
HCV genotipe 3 infected patients 2,706 11.0 [17]
Table I. Epidemiological data and number of HCV genotype 3 infected patients eligible to treatment
Health states transition rate source
F3 → F4 0.112 [18]
F4 → Decompensated cirrhosis 0.039
[19]
F4 → HCC 0.014
Decompensated cirrhosis → HCC 0.014
Decompensated cirrhosis → Transplant 0.030
Decompensated cirrhosis → Death 0.130
HCC → Transplant 0.030
HCC → Death 0.430
Transplant (Year 1) → Death 0.210
Transplant (Year 2+) → Death 0.057
Table II. Model’s health states transition rates
antiviral  
treatment
sVr at 
12 weeks (%)
anemia 
(%)
rash  
(%)
SOF + DCV + RBV – 24 weeks 100 [20] 10.3 [21] 6.9 [21]
INF-α + RBV + SOF – 12 weeks 92.1 [22-24] 12.0 [22] 12.0 [22]
Table III. Effectiveness and adverse events rates of the two treatments
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and direct medical costs for the management 
of the therapies’ adverse events.
All costs refer to 2015, those derived from 
published articles were converted using the 
Italian yearly average inflation rates as repor-
ted by the International Monetary Fund [25]. 
The cost of the antiviral therapies considered 
were based on the price published in the Offi-
cial Gazette of the Italian Medicines Agency 
[26-29]. The costs of the management of ad-
verse events were calculated using an activity 
based costing approach, through interviews 
with clinical experts and are therefore based 
on the Italian real clinical practice. The cost 
of death was calculated by multiplying by 
12.5 the average cost of 3 months in health 
states F3 and F4 [30]. The costs considered 
are reported in Table IV.
Univariate and multivariate sensitivity 
analyses were performed to test the robust-
ness of the results. The parameters changed 
were the cost of DCV (±10%); the effective-
ness of DCV (-5%) and the number of pa-
tients eligible for antiviral treatment (±10%).
Cost category Cost yearly / per event / per treatment cycle (€) source
F3 302.0 [8]
F4 426.8 [8]
Decompensated cirrhosis 6,720.2 [8]
HCC 7,470.0 [8]
Transplant (year 1) 84,093.8 [8]
Transplant (year 2+) 4,958.7 [8]
Death 1,138.7 Reprocessed from [8,30]
Anemia 38.7 Expert opinion
Rash 34.6 Expert opinion
SOF + DCV + RBV – 24 weeks1 55,560.0 [26-29]
INF-α + RBV + SOF – 12 weeks1 39,809.0 [26-29]
Table IV. Costs considered in the model
1 Ex-factory negotiated net price considering confidential agreements
results
The results of the analysis are reported in Ta-
ble V.
The use of DCV would lead to an increase of 
the costs for the Italian NHS in the five ye-
ars considered in the analysis. In details, the 
costs increase is due to the cost of treatment, 
while the costs related to the management of 
patients conditions in terms of health state 
and to the management of the adverse events 
decrease in the first year (- 3,258 €), increase 
in year 2 (+ 43,215 €) and exponentially de-
crease in the last three years of the analysis 
(-73,254 €, -179,154 € and -9,203,706 €, re-
spectively). The total impact on the budget 
of the Italian NHS increase, compared to the 
previous year in the second and third year (+ 
0.22% and + 9.43%) and decrease in the last 
two years (- 0.45% and -29.63%).
The sensitivity analysis results are reported 
in Table VI.
All scenarios show the same trends of the base 
case analysis and show a budget impact with 
yearly variations lower than 6 million euros.
scenario
Cost 
category
Costs (€)
Year 2015 Year 2016 Year 2017 Year 2018 Year 2019 Total
Without DCV Treatment 107,723,154 107,723,154 107,723,154 107,723,154 107,723,154 538.615.770
HS and AE 9,705,386 14,603,436 14,835,723 15,056,818 24,168,852 78,370,216
Total 117,428,540 122,326,590 122,558,877 122,779,972 131,892,006 616,985,986
With DCV Treatment 129,034,257 129,034,257 131,165,367 131,165,367 133,296,478 653.695.726
HS and AE 9,702,128 14,646,651 14,762,469 14,877,664 14,965,146 68.954.059
Total 138,736,385 143,680,908 145,927,836 146,043,031 148,261,623 722.649.785
Budget 
impact
Treatment 21,311,103 21,311,103 23,442,213 23,442,213 25,573,324 115,079,956
HS and AE - 3,258 43,215 - 73,254 - 179,154 - 9,203,706 - 9,416,157
Total 21,307,845 21,354,318 23,368,959 23,263,059 16,369,618 105,663,799
Table V. Impact on the budget of the Italian NHS of the use of DCV for the treatment of HCV genotype 3 infected patients
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discussion
New HCV antiviral treatments, due to their 
high effectiveness compared with previously 
available treatments, give the opportunity to 
cure the infection and substantially reduce its 
prevalence. Few studies investigated the cost 
effectiveness of DCV for the treatment of 
HCV genotype 3 infection [31,32], however 
Figure 1. Impact on the budget of the Italian NHS of the use of DCV for the treatment of HCV genotype 3 infected patients
scenario
Costs (€)
Year 2015 Year 2016 Year 2017 Year 2018 Year 2019
Base case 21,307,845 21,354,318 23,368,959 23,263,059 16,369,618
DCV cost -10% 19,007,745 19,054,218 20,838,849 20,732,949 13,609,498
DCV cost +10% 23,607,945 23,654,418 25,899,069 25,793,169 19,129,738
DCV effectiveness -5% 21,307,845 21,325,040 23,419,717 23,384,465 16,570,992
Number of patients eligible to antiviral treatments -10% 19,177,060 19,218,887 21,032,063 20,936,753 14,732,656
Number of patients eligible to antiviral treatments +10% 23,438,629 23,489,750 25,705,855 25,589,365 18,006,579
DCV cost -10% and DCV effectiveness -5% 19,007,745 19,024,940 20,889,607 20,854,355 13,810,872
DCV cost +10% and DCV effectiveness -5% 23,607,945 23,625,140 25,949,827 25,914,575 19,331,112
DCV cost -10%, DCV effectiveness -5% and number of 
patients eligible to antiviral treatments +10%
20,908,519 20,927,434 22,978,568 22,939,790 15,191,959
DCV cost +10%, DCV effectiveness -5% and number of 
patients eligible to antiviral treatments +10%
25,968,739 25,987,654 28,544,810 28,506,032 21,264,223
DCV cost -10%, DCV effectiveness -5% and number of 
patients eligible to antiviral treatments -10%
17,106,970 17,122,446 18,800,647 18,768,919 12,429,785
DCV cost +10%, DCV effectiveness -5% and number of 
patients eligible to antiviral treatments -10%
21,247,150 21,262,626 23,354,845 23,323,117 17,398,001
DCV cost +10%, and number of patients eligible to 
antiviral treatments +10%
25,968,739 26,019,860 28,488,976 28,372,486 21,042,711
DCV cost +10% and number of patients eligible to 
antiviral treatments -10%
21,247,150 21,288,977 23,309,162 23,213,852 17,216,764
DCV cost -10%, and number of patients eligible to antiviral 
treatments +10%
20,908,519 20,959,640 22,922,734 22,806,244 14,970,447
DCV cost -10% and number of patients eligible to antiviral 
treatments -10%
17,106,970 17,148,797 18,754,964 18,659,654 12,248,548
Table VI. Yearly budget impact resulting from the sensitivity analysis performed
to our knowledge its impact on national bud-
get was not investigated so far. These econo-
mic evaluation may provide information on 
the efficiency of the resource allocation, but 
not on the sustainability of the treatment stra-
tegy.
The analysis performed show an increase of 
costs for the treatment of HCV genotype 3 
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infected patients for the Italian NHS in the 
five years considered. The cost increase is 
due to the cost of the antiviral treatment, 
while the direct medical costs related to the 
management of the patients’ health state and 
of therapy related adverse events constantly 
decrease after the second year. The dyna-
mics of cost reduction (-73,254 €, -179,154 
€ and -9,203,706 € in the last three years of 
the analysis) suggest the possibility to com-
pensate over the years the higher cost of the 
treatment with the cost reduction for the ma-
nagement of patients improved health condi-
tions.
The model is based on published data related 
to the Italian context. However, the number 
of HCV infected patients and the rate of ge-
notype 3 infection are still discussed within 
the scientific community. Moreover, the ef-
fectiveness of therapies in genotype 3 HCV 
infected patients is based on studies with li-
mited samples due to the lower prevalence 
of this genotype compared with other HCV 
genotypes.
The main limit of the analysis is related to the 
5 year time horizon considered. The higher 
effectiveness of DCV+ SOF + RBV compa-
red with INF-α + RBV + SOF, lead to a de-
crease in the number of patients infected with 
HCV. The direct medical costs of the ma-
nagement of HCV infection increase in the 
long period (due to decompensated cirrhosis, 
HCC and liver transplant), therefore the bud-
get impact of the use of DCV+ SOF + RBV 
is likely to be overestimated in the analysis 
presented, not considering the therapy’s long 
term benefits.
conclusion
The use of DCV for the treatment of HCV 
genotype 3 infected patients in the Italian 
context is likely to have a short term impact 
on the budget of the Italian NHS increasing 
the resources use compared to the sole use 
of INF-α + RBV + SOF. However, in the five 
years analysis there is a trend of reduction in 
the cost of the management of health states 
and adverse events with DCV+ SOF + RBV, 
compared with INF-α + RBV + SOF, which 
may lead to the possibility to reduce costs in 
the long term.
acknowledgeMents
Professional medical writing and editorial as-
sistance was provided by Lazzarin A, PhD, 
and Alfredo A, PhD, and was funded by Bri-
stol-Myers Squibb.
references
1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect. 2011; 17: 107-15; http://dx.doi.
org/10.1111/j.1469-0691.2010.03432.x
2. Mohd Hanafiah K, Groeger J, Flaxman AD, et al. Global epidemiology of hepatitis C virus infection: new estimates 
of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-42; http://dx.doi.org/10.1002/hep.26141
3. Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. 
J Hepatol 2014; 61(1 Suppl): S45-57; http://dx.doi.org/10.1016/j.jhep.2014.07.027
4. Mühlberger N, Schwarzer R, Lettmeier B, et al. HCV-related burden of disease in Europe: a systematic assessment 
of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009; 9: 34; http://dx.doi.org/10.1186/1471-
2458-9-34
5. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61(1 Suppl): S58-68; http://dx.doi.
org/10.1016/j.jhep.2014.07.012
6. Marcellusi A, Viti R, Capone A, Mennini FS. The economic burden of HCV-induced diseases in Italy. A probabilistic 
cost of illness model. Eur Rev Med Pharmacol Sci 2015; 19: 1610-20
7. Vietri J, Prajapati G, El Khoury AC. The burden of hepatitis C in Europe from the patients’ perspective: a survey 
in 5 countries. BMC Gastroenterol 2013; 13: 16; http://dx.doi.org/10.1186/1471-230X-13-16
8. Mennini FS, Marcellusi A, Andreoni M, et al. Health policy model: long-term predictive results associated with the 
management of hepatitis C virus-induced diseases in Italy. Clinicoecon Outcomes Res 2014; 6: 303-10
9. Razavi H, Elkhoury AC, Elbasha E, et al. Chronic hepatitis C virus (HCV) disease burden and cost in the United 
States. Hepatology 2013; 57: 2164-70; http://dx.doi.org/10.1002/hep.26218
10. Nkontchou G, Ziol M, Aout M, et al. HCV genotype 3 is associated with a higher hepatocellular carcinoma inci-
dence in patients with ongoing viral C cirrhosis. J Viral Hepat 2011; 18: e516-22; http://dx.doi.org/10.1111/j.1365-
2893.2011.01441.x
© SEEd All rights reserved12 Farmeconomia. Health economics and therapeutic pathways 2016; 17(1)
Budget impact analysis of the use of daclatasvir in Italy for the treatment of Hepatitis C Virus (HCV) genotype 3 patients
11. Bochud PY, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic 
hepatitis C. J Hepatol 2009; 51: 655-66; http://dx.doi.org/10.1016/j.jhep.2009.05.016
12. European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol 
2015; 63: 199-236; http://dx.doi.org/10.1016/j.jhep.2015.03.025
13. Sullivan SD, Mauskopf JA, Augustovski F, et al. Budget impact analysis-principles of good practice: report of 
the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. Value Health 2014; 17: 5-14; http://dx.doi.
org/10.1016/j.jval.2013.08.2291
14. Italian Institute of Statistics, Population data referred to 2014. Available at: http://demo.istat.it/pop2014/index.html
15. Ansaldi F, Bruzzone B, Salmaso S, et al. Different seroprevalence and molecular epidemiology patterns of hepatitis 
C virus infection in Italy. J Med Virol 2005; 76: 327-32; http://dx.doi.org/10.1002/jmv.20376
16. Marcellusi A, Viti R, Capone A, et al. Costi diretti e indiretti assorbiti dalle patologie HCV-indotte in Italia: stima 
basata su una metodologia probabilistica di Cost of Illness. PharmacoEconomics Italian Research Articles 2014; 
16: 23; http://dx.doi.org/10.1007/s40276-014-0023-9
17. Italian Platform for the Study of Viral Hepatitis (PITER) – database
18. Thein HH, Yi Q, Dore GJ, et al. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus 
infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-31; http://dx.doi.org/10.1002/hep.22375
19. Martin NK, Vickerman P, Miners A, et al. Cost-effectiveness of hepatitis C virus antiviral treatment for injection 
drug user populations. Hepatology 2012; 55: 49-57; http://dx.doi.org/10.1002/hep.24656
20. European Medicines Agency. Daklinza Annex 1 – Summary of products caracteristics. Available at: http://www.
ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003768/WC500172848.pdf
21. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or 
untreated chronic HCV infection. N Engl J Med 2014; 370: 211-21; http://dx.doi.org/10.1056/NEJMoa1306218
22. Lawitz E, Lalezari JP, Hassanein T, et al. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for 
non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, 
phase 2 trial. Lancet Infect Dis 2013; 13: 401-8; http://dx.doi.org/10.1016/S1473-3099(13)70033-1
23. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis 
C. N Engl J Med 2013; 368: 34-44; http://dx.doi.org/10.1056/NEJMoa1208953
24. Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin 
in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an 
open-label, randomised, phase 2 trial. Lancet 2014; 383: 515-23; http://dx.doi.org/10.1016/S0140-6736(13)62121-2
25. International Monetary Fund. World Economic Outlook Database, April 2014. Available at: http://www.imf.org/
external/pubs/ft/weo/2015/01/weodata/index.aspx
26. Italian Medicines Agency (AIFA). Regime di rimborsabilità e prezzo del medicinale per uso umano «Sovaldi» (so-
fosbuvir), autorizzata con procedura centralizzata europea dalla Commissione europea. (Determina n. 1353/2014). 
(14A09382) (GU Serie Generale n.283 del 5-12-2014)
27. Italian Medicines Agency (AIFA). Regime di rimborsabilità e prezzo del medicinale per uso umano «Daklinza 
(daclatasvir)». (Determina n. 495/2015). (15A03388) (GU Serie Generale n.101 del 4-5-2015)
28. Italian Medicines Agency (AIFA). Regime di rimborsabilità e prezzo di vendita del medicinale per uso umano 
«Ribavirina Mylan» (ribavirina) autorizzata con procedura centralizzata europea dalla Commissione europea. 
(Determina n. 38/2013). (13A00836) (GU Serie Generale n.30 del 5-2-2013)
29. Italian Medicines Agency (AIFA). Autorizzazione all›immissione in commercio della specialità medicinale per uso 
umano «Roferon A» (GU Serie Generale n.84 del 9-4-2004)
30. Raitano M. The Impact of Death-Related Costs on Health-Care Expenditure: A Survey. ENEPRI Research Report 
No. 17/February 2006
31. Moshyk A, Martel MJ, Tahami Monfared AA, et al. Cost-effectiveness of daclatasvir plus sofosbuvir-based regimen 
for treatment of hepatitis C virus genotype 3 infection in Canada. J Med Econ 2016; 19: 181-92; http://dx.doi.org
/10.3111/13696998.2015.1106546
32. Najafzadeh M, Andersson K, Shrank WH, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis 
C virus. Ann Intern Med 2015; 162: 407-19; http://dx.doi.org/10.7326/M14-1152
